In vivo intracellular signaling as a marker of antiangiogenic activity

Carmen C. Solorzano, Lee M. Ellis, Young D. Jung, Corazon D. Bucana, David J. McConkey, Gary E. Gallick, Lee M. Ellis, Gerald McMahon

Research output: Contribution to journalArticle

Abstract

Alterations in endothelial cell (EC) signaling could serve as a marker of effective antiangiogenic therapy. We determined the effect of an antiangiogenic tyrosine kinase inhibitor, SU6668, on tumor EC signaling in liver metastases in mice. In vitro immunofluorescence verified that pretreatment of ECs with SU6668 before exposure to VEGF decreased in vitro phosphorylation of Erk and Akt. Using double-fluorescence immunohistochemistry, phosphorylated Erk and Akt were constitutively expressed in ECs in liver metastases in untreated mice, but SU6668 blocked activation of these signaling intermediates. Determining the activation status of the Erk and Akt signaling pathways in tumor ECs may serve as a surrogate marker for the effectiveness of antiangiogenic regimens.

Original languageEnglish (US)
Pages (from-to)7048-7051
Number of pages4
JournalCancer Research
Volume61
Issue number19
StatePublished - Oct 1 2001
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vivo intracellular signaling as a marker of antiangiogenic activity'. Together they form a unique fingerprint.

  • Cite this

    Solorzano, C. C., Ellis, L. M., Jung, Y. D., Bucana, C. D., McConkey, D. J., Gallick, G. E., Ellis, L. M., & McMahon, G. (2001). In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Research, 61(19), 7048-7051.